[article]
| Titre : |
Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats |
| Type de document : |
texte imprimé |
| Auteurs : |
Alan Cowan, Auteur |
| Année de publication : |
2016 |
| Article en page(s) : |
p. 18-27 |
| Langues : |
Anglais (eng) |
| Mots-clés : |
Analgesics, Opioid/adverse effects* Animals Body Weight/drug effects Buprenorphine/adverse effects* Delayed-Action Preparations Dose-Response Relationship, Drug Female Injections, Subcutaneous Male Nausea/chemically induced Postoperative Period Rats, Inbred F344 Analgesics, Opioid Buprenorphine |
| Résumé : |
Abstract
Extended-release buprenorphine is an effective analgesic in laboratory animals, and its safety has been established in mice but not in rats. The authors used a target animal safety trial to evaluate the safety of extended-release buprenorphine in rats. Fischer 344 rats received post-surgical subcutaneous injections of 1.3 mg, 3.9 mg or 6.5 mg buprenorphine per kg body weight (two times, six times or ten times the intended dose, respectively), and their body weight, clinical signs and symptoms, clinical pathology and histopathology were monitored for 4 d. Body weight was not significantly different in rats that received buprenorphine compared with control rats. Signs of nausea-related behavior were observed in 25% of the rats treated with buprenorphine. Clinical pathology results for all rats were normal, and gross and microscopic histopathology examinations identified no substantial abnormalities, suggesting that this behavior was of minor consequence. Other adverse events previously reported to occur with opiate therapy, including weight loss and dermal lesions at drug injection sites, were not observed in this study. The results of this study show that post-surgical administration of an extended-release buprenorphine product is safe in Fischer 344 rats and does not necessarily cause substantial adverse effects, confirming that opiate therapy is a viable choice in laboratory animal medicine. |
| Permalink : |
./index.php?lvl=notice_display&id=66490 |
in LabAnimal-Europe > 02/16 (février 2016) . - p. 18-27
[article] Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats [texte imprimé] / Alan Cowan, Auteur . - 2016 . - p. 18-27. Langues : Anglais ( eng) in LabAnimal-Europe > 02/16 (février 2016) . - p. 18-27
| Mots-clés : |
Analgesics, Opioid/adverse effects* Animals Body Weight/drug effects Buprenorphine/adverse effects* Delayed-Action Preparations Dose-Response Relationship, Drug Female Injections, Subcutaneous Male Nausea/chemically induced Postoperative Period Rats, Inbred F344 Analgesics, Opioid Buprenorphine |
| Résumé : |
Abstract
Extended-release buprenorphine is an effective analgesic in laboratory animals, and its safety has been established in mice but not in rats. The authors used a target animal safety trial to evaluate the safety of extended-release buprenorphine in rats. Fischer 344 rats received post-surgical subcutaneous injections of 1.3 mg, 3.9 mg or 6.5 mg buprenorphine per kg body weight (two times, six times or ten times the intended dose, respectively), and their body weight, clinical signs and symptoms, clinical pathology and histopathology were monitored for 4 d. Body weight was not significantly different in rats that received buprenorphine compared with control rats. Signs of nausea-related behavior were observed in 25% of the rats treated with buprenorphine. Clinical pathology results for all rats were normal, and gross and microscopic histopathology examinations identified no substantial abnormalities, suggesting that this behavior was of minor consequence. Other adverse events previously reported to occur with opiate therapy, including weight loss and dermal lesions at drug injection sites, were not observed in this study. The results of this study show that post-surgical administration of an extended-release buprenorphine product is safe in Fischer 344 rats and does not necessarily cause substantial adverse effects, confirming that opiate therapy is a viable choice in laboratory animal medicine. |
| Permalink : |
./index.php?lvl=notice_display&id=66490 |
|  |
Ajouter le résultat dans votre panier Faire une suggestion Affiner la rechercheLack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats in LabAnimal-Europe, 02/16 (février 2016)
